Hospital Outcomes of Community-Acquired SARS-CoV-2 Omicron Variant Infection Compared With Influenza Infection in Switzerland.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
entrez:
15
2
2023
pubmed:
16
2
2023
medline:
18
2
2023
Statut:
epublish
Résumé
With the ongoing COVID-19 pandemic, it is crucial to assess the current burden of disease of community-acquired SARS-CoV-2 Omicron variant in hospitalized patients to tailor appropriate public health policies. Comparisons with better-known seasonal influenza infections may facilitate such decisions. To compare the in-hospital outcomes of patients hospitalized with the SARS-CoV-2 Omicron variant with patients with influenza. This cohort study was based on a national COVID-19 and influenza registry. Hospitalized patients aged 18 years and older with community-acquired SARS-CoV-2 Omicron variant infection who were admitted between January 15 and March 15, 2022 (when B.1.1.529 Omicron predominance was >95%), and hospitalized patients with influenza A or B infection from January 1, 2018, to March 15, 2022, where included. Patients without a study outcome by August 30, 2022, were censored. The study was conducted at 15 hospitals in Switzerland. Community-acquired SARS-CoV-2 Omicron variant vs community-acquired seasonal influenza A or B. Primary and secondary outcomes were defined as in-hospital mortality and admission to the intensive care unit (ICU) for patients with the SARS-CoV-2 Omicron variant or influenza. Cox regression (cause-specific and Fine-Gray subdistribution hazard models) was used to account for time-dependency and competing events, with inverse probability weighting to adjust for confounders with right-censoring at day 30. Of 5212 patients included from 15 hospitals, 3066 (58.8%) had SARS-CoV-2 Omicron variant infection in 14 centers and 2146 patients (41.2%) had influenza A or B in 14 centers. Of patients with the SARS-CoV-2 Omicron variant, 1485 (48.4%) were female, while 1113 patients with influenza (51.9%) were female (P = .02). Patients with the SARS-CoV-2 Omicron variant were younger (median [IQR] age, 71 [53-82] years) than those with influenza (median [IQR] age, 74 [59-83] years; P < .001). Overall, 214 patients with the SARS-CoV-2 Omicron variant (7.0%) died during hospitalization vs 95 patients with influenza (4.4%; P < .001). The final adjusted subdistribution hazard ratio (sdHR) for in-hospital death for SARS-CoV-2 Omicron variant vs influenza was 1.54 (95% CI, 1.18-2.01; P = .002). Overall, 250 patients with the SARS-CoV-2 Omicron variant (8.6%) vs 169 patients with influenza (8.3%) were admitted to the ICU (P = .79). After adjustment, the SARS-CoV-2 Omicron variant was not significantly associated with increased ICU admission vs influenza (sdHR, 1.08; 95% CI, 0.88-1.32; P = .50). The data from this prospective, multicenter cohort study suggest a significantly increased risk of in-hospital mortality for patients with the SARS-CoV-2 Omicron variant vs those with influenza, while ICU admission rates were similar.
Identifiants
pubmed: 36790812
pii: 2801464
doi: 10.1001/jamanetworkopen.2022.55599
pmc: PMC9932839
doi:
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2255599Investigateurs
Sarah Tschudin-Sutter
(S)
Ulrich Heininger
(U)
Philipp Jent
(P)
Michael Büttcher
(M)
Yvonne Nussbaumer
(Y)
Danielle Vuichard Gysin
(D)
Christoph Berger
(C)
Domenica Flury
(D)
Marie-Céline Zanella Terrier
(MC)
Références
Euro Surveill. 2022 Jan;27(4):
pubmed: 35086614
Emerg Microbes Infect. 2022 Dec;11(1):1742-1750
pubmed: 35730665
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Nat Med. 2022 Sep;28(9):1933-1943
pubmed: 35675841
Int J Infect Dis. 2021 Feb;103:316-322
pubmed: 33279652
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
Saudi J Anaesth. 2019 Apr;13(Suppl 1):S31-S34
pubmed: 30930717
Lancet Infect Dis. 2021 Nov;21(11):1507-1517
pubmed: 34171231
Lancet Reg Health West Pac. 2022 Mar;20:100365
pubmed: 35005672
Int J Infect Dis. 2022 Mar;116:38-42
pubmed: 34971823
Am J Epidemiol. 2009 Jul 15;170(2):244-56
pubmed: 19494242
Euro Surveill. 2022 Jan;27(1):
pubmed: 34991775
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
J Intensive Care. 2020 Sep 14;8:70
pubmed: 32939266
Emerg Med Pract. 2021 Feb 01;23(Suppl 2):CD1-CD2
pubmed: 33529515